1. Mc Goldrick, Rory., Evgenia, Thodorakoploulos., Azzopardi, Ernest. & Murison, Maxwell. (0). Lasers and ancillary treatments for scar management Part 2: Keloid, hypertrophic, pigmented and acne scars.. Scars Burns and Healing 3, 69-81.

   https://cronfa.swan.ac.uk/Record/cronfa47906 doi:https://doi.org/10.1177/2059513116689805
2. Marsden, Nicholas J.., Van, Martin., Dean, Samera., Azzopardi, Ernest A.., Hemington-Gorse, Sarah., Evans, Phillip A.. & Whitaker, Iain S.. (2017). Measuring coagulation in burns: an evidence-based systematic review. Scars, Burns & Healing 3, 205951311772820

   https://cronfa.swan.ac.uk/Record/cronfa40079 doi:10.1177/2059513117728201
3. Teixeira, Sofia Rodrigues., Lloyd, Catherine., Yao, Seydou., Andrea Salvatore Gazze, Whitaker, Iain S.., Francis, Lewis., Conlan, R. Steven. & Azzopardi, Ernest. (2016). Polyaniline-graphene based α-amylase biosensor with a linear dynamic range in excess of 6 orders of magnitude. Biosensors and Bioelectronics 85, 395-402.

   https://cronfa.swan.ac.uk/Record/cronfa27755 doi:10.1016/j.bios.2016.05.034
4. Azzopardi, E., Owens, S., Murison, M., Rees, D., Anne Sawhney, M., Francis, L., Sofia Rodrigues Teixeira, R., Clement, M., Steven Conlan, R. & Whitaker, I. (2017). Chromophores in operative surgery: Current practice and rationalized development. Journal of Controlled Release 249, 123-130.

   https://cronfa.swan.ac.uk/Record/cronfa31767 doi:10.1016/j.jconrel.2016.12.044
5. Azzopardi, E., Lloyd, C., Rodrigues Teixeira, S., Conlan, R. & Whitaker, I. (2016). Clinical applications of amylase: Novel perspectives. Surgery

   https://cronfa.swan.ac.uk/Record/cronfa27414 doi:10.1016/j.surg.2016.01.005

See more...

• PMNM04 Nanomedicines and Therapeutics

  The module will explore the history and development of molecular medicines. Using landmark technology and chemical development phases, the traditional small chemical entities using in molecular medicine will be outlined, using drugs such as taxols and tamoxifen as exemplars. The common target oncology and non oncology disorders will outlined and their respective targets for such medicines detailed alongside drug modes of action and delivery (IV and oral). Further exploration of targeted nanoparticle delivery, from early first generation drugs such as Abraxane to second generation biologically targeted SMART delivery systems, will expand the knowledge to future molecular medicines such as antibody drug conjugates and kinase inhibitors. Excitingly the module will include guest lectures from industry and clinicians, covering the spectrum of drug development to delivery and clinical considerations.

• no change (current)

  Student name: Anne Sawhney

  PhD

  Other supervisor: Prof Steve Conlan